NCT07680582 — Ruijin Hospital neoantigen vaccine trial
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
Registry record
| Registry ID | NCT07680582 ↗ |
|---|---|
| Lead sponsor | Ruijin Hospital |
| Collaborators | Abogen Life Sciences (Shanghai) Co., Ltd., Suzhou Abogen Biosciences Co., Ltd. |
| Phase | Phase EARLY_PHASE1 |
| Status | Recruiting |
| Indication | Solid Tumor |
| Enrollment | 60 participants (target) |
| Start date | 2026-06-09 |
| Primary completion | 2028-06-30 (est.) |
| Last registry update | 3 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07680582), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT07680582?
NCT07680582 (An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by Ruijin Hospital.
Is NCT07680582 recruiting?
As of the 2026-08-03 registry update, NCT07680582 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07680582?
The lead sponsor is Ruijin Hospital. Collaborators: Abogen Life Sciences (Shanghai) Co., Ltd., Suzhou Abogen Biosciences Co., Ltd..
What condition does NCT07680582 study?
The registered condition is Solid Tumor. Primary completion is listed as 2028-06-30 (estimated).
Are results available for NCT07680582?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07680582.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.